Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
Same author

Evaluation of Alternative Smoking Duration Criteria for Lung Cancer Screening.

JAMA internal medicine·2026
Same author

Increasing power and robustness in screening trials by testing stored specimens in the control arm.

BMC medical research methodology·2026
Same author

Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline.

JCO oncology practice·2026
Same author

Brief Report: Improving Lung Cancer Screening Rates: A Pilot Program for Low-Dose CT Implementation in a Community Cancer Center.

Clinical lung cancer·2026
Same author

Subsequent risk of lung cancer in patients with positive low-dose CT screens and initial negative lung biopsy.

Lung cancer (Amsterdam, Netherlands)·2026

相关实验视频

Updated: May 12, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

使用大型独立参考集 (联盟A212102) 执行多项多种癌症检测测试.

Marie Wood1, Paul F Pinsky2, Paul Novotny3

  • 1Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA.

Journal of the National Cancer Institute
|January 7, 2026
PubMed
概括

多种癌症检测 (MCD) 试验的性能各不相同,与晚期相比,对早期癌症的敏感性明显较低. 原产地组织准确率为75%.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.4K

相关实验视频

Last Updated: May 12, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.4K

科学领域:

  • 在瘤学瘤学.
  • 生物技术是生物技术.
  • 医学诊断 医学诊断 医学诊断

背景情况:

  • 评估多种癌症检测 (MCD) 试验需要强大的参考集合.
  • 美国国家癌症研究所 (NCI) 发起了联盟的参考研究,以评估MCD的临床试验适用性.

研究的目的:

  • 用标准化参考集评估多个MCD试验的性能.
  • 评估MCD试验的灵敏度,特异性和起源组织预测准确性.

主要方法:

  • 招募了患有癌症的个人和对照,收集治疗前的血液.
  • 设计了一项性能评估研究,使用来自6家参与公司的参考样本.
  • 针对向性,非向性和控制性癌症类型的测试样本,报告电话,风险得分和原始组织预测.

主要成果:

  • 包括549例癌症 (13种类型) 和413例对照.
  • 中位特异性为92.3%.
  • 通过阳性/阴性呼叫 (SEPN) 的中位敏感度为32% (早期阶段) 和73% (晚期);在98%的特异性 (SE98) 时,19% (早期) 和66% (晚期). 中位数的起源组织准确度为75%.

结论:

  • 测试灵敏度和特异性显示出相当大的差异.
  • 早期癌症检测灵敏度明显低于晚期癌症检测.
  • 组织起源预测的准确性需要进一步改进.